- Home
- RIGL vs GRAF Comparison
RIGL vs GRAF Comparison
Compare RIGL & GRAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- GRAF
- Stock Information
- Founded
- RIGL 1996
- GRAF 2021
- Country
- RIGL United States
- GRAF United States
- Employees
- RIGL N/A
- GRAF N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- GRAF
- Sector
- RIGL Health Care
- GRAF
- Exchange
- RIGL Nasdaq
- GRAF NYSE
- Market Cap
- RIGL 247.1M
- GRAF 288.1M
- IPO Year
- RIGL 2000
- GRAF 2024
- Fundamental
- Price
- RIGL $22.07
- GRAF $10.01
- Analyst Decision
- RIGL Buy
- GRAF
- Analyst Count
- RIGL 4
- GRAF 0
- Target Price
- RIGL $31.13
- GRAF N/A
- AVG Volume (30 Days)
- RIGL 151.9K
- GRAF 45.1K
- Earning Date
- RIGL 11-07-2024
- GRAF 01-01-0001
- Dividend Yield
- RIGL N/A
- GRAF N/A
- EPS Growth
- RIGL N/A
- GRAF N/A
- EPS
- RIGL 0.22
- GRAF N/A
- Revenue
- RIGL $156,374,000.00
- GRAF N/A
- Revenue This Year
- RIGL $38.26
- GRAF N/A
- Revenue Next Year
- RIGL $24.21
- GRAF N/A
- P/E Ratio
- RIGL $99.67
- GRAF N/A
- Revenue Growth
- RIGL 19.95
- GRAF N/A
- 52 Week Low
- RIGL $7.48
- GRAF $9.03
- 52 Week High
- RIGL $22.85
- GRAF $11.02
- Technical
- Relative Strength Index (RSI)
- RIGL 83.76
- GRAF N/A
- Support Level
- RIGL $13.91
- GRAF N/A
- Resistance Level
- RIGL $14.70
- GRAF N/A
- Average True Range (ATR)
- RIGL 1.04
- GRAF 0.00
- MACD
- RIGL 0.50
- GRAF 0.00
- Stochastic Oscillator
- RIGL 91.59
- GRAF 0.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About GRAF GRAF GLOBAL CORP
Graf Global Corp is a blank check company.